Heteromultivalent ligand-decoration for actively targeted nanomedicine

Biomaterials

Volumn 35, Issue 9, 2014, Pages 2568-2579

  Modery Pawlowski, Christa L ^a   Sen Gupta, Anirban ^a  

^a Case Western Reserve University   (United States)

Author keywords

Active targeting; Heteromultivalent; Ligands; Nanomedicine; Receptors

Indexed keywords

ACTIVE TARGETING; HETEROMULTIVALENT; LIGANDS; NANOMEDICINE; RECEPTORS;

ANIMALS; DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NANOMEDICINE; RECEPTORS, CELL SURFACE;

EID: 84894948077     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.047     Document Type: Review

References (100)

1. Ehrlich P. Beiträge zur theorie und praxis der histologischen färbung 1878, [Thesis], Univ Leipzig.
2. Ehrlich P. Aus theorie und praxis der chemotherapie. Folia Serologica 1911, 7:697-714.
3. Feynman R.P. There's plenty of room at the bottom. Eng Sci 1960, 23(5):22-36.
4. Taniguchi N. On the basic concept of 'nano-technology'. Proc Intl Conf Prod Eng Tokyo, Part II, Japan Society of Precision Engineering 1974.
5. Drexler E.P. Engines of creation: the coming era of nanotechnology 1986, Anchor Books, New York.
6. Freitas R.A. Nanomedicine, volume I: basic capabilities 1999, Landes Biosciences, Austin.
7. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech 2007, 2:751-760.
8. Cho K., Wang X., Nie S., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14(5):1310-1316.
9. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
10. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010, 148:135-146.
11. Yu M.K., Park J., Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2(1):3-44.
12. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60(15):1615-1626.
13. Chen W.C., Zhang A.X., Li S.D. Limitations and niches of the active targeting approach for nanoparticle drug delivery. Eur J Nanomed 2012, 4(2-4):89-93.
14. Master A.M., Sen Gupta A. EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine 2012, 7(12):1895-1906.
15. Liao C., Sun Q., Liang B., Shen J., Shuai X. Targeting EGFR-overexpressing tumor cells using cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide. Eur J Radiol 2011, 80(3):699-705.
16. Kim I.Y., Kang Y.S., Lee D.S., Park H.J., Choi E.K., Oh Y.K., et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release 2009, 140(1):55-60.
17. Kularatne S.A., Low P.S. Targeting of nanoparticles: folate receptor. Methods Mol Biol 2010, 624:249-265.
18. Garcia-Bennett A., Nees M., Fadeel B. In search of the Holy Grail: folate-targeted nanoparticles for cancer therapy. Biochem Pharmacol 2011, 81(8):976-984.
19. Teow Y., Valiyaveettil S. Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles. Nanoscale 2010, 2:2607-2613.
20. Yang X., Koh C.G., Liu S., Pan X., Santhanam R., Yu B., et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm 2009, 6(1):221-230.
21. Daniels T.R., Bernabeu E., Rodríguez J.A., Patel S., Kozman M., Chiappetta D.A., et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012, 1820(3):291-317.
22. Daniels T.R., Delgado T., Helguera G., Penichet M.L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2005, 121(2):159-176.
23. Sen Gupta A. Nanomedicine approaches in vascular disease: a review. Nanomedicine: NBM 2011, 7(6):763-779.
24. Koren E., Torchilin V.P. Drug carriers for vascular drug delivery. IUBMB Life 2011, 63(8):586-595.
25. Buxton D.B. Current status of nanotechnology approaches for cardiovascular disease: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1(2):149-155.
26. Iverson N., Plourde N., Chnari E., Nackman G.B., Moghe P.V. Convergence of nanotechnology and cardiovascular medicine: progress and emerging prospects. BioDrugs 2008, 22(1):1-10.
27. Jain S., Doshi A.S., Iyer A.K., Amiji M.M. Multifunctional nanoparticles for targeting cancer and inflammatory diseases. J Drug Target 2013, 21(10):888-903.
28. Kamaly N., Fredman G., Subramanian M., Gadde S., Pesic A., Cheung L., et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A 2013, 110(16):6506-6511.
29. Zolnik B.S., González-Fernández A., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151(2):458-465.
30. Silva J.M., Videira M., Gaspar R., Préat V., Florindo H.F. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013, 168(2):179-199.
31. Ventola C.L. The nanomedicine revolution part 2: current and future applications. Pharm Therapeut 2012, 37(10):582-591.
32. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010, 624:25-37.
33. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188(6):759-768.
34. ® ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99-105.
35. Tan Y., Chiow K.H., Huang D., Wong S.H. Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A-431) cells. Br J Pharm 2010, 159:1497-1510.
36. Ramamurth G., Broome A.M., Lavik K., Verma A., Basilion J.P. Imaging the coordinated expression of cell surface receptors in gliomas using a novel multifunctional enzyme reporter complementation complex. Proceedings: AACR 102nd Annual Meeting, Cancer Research 2011, vol. 71(8). Suppl. 1.
37. Bossi P., Locati L.D., Licitra L. Folate in head and neck squamous cell cancer chemoprevention: purposely left outα. J Clin Oncol 2008, 26(20):3463-3471.
38. Shin E.Y., Lee B.H., Yang J.H., Shin K.S., Lee G.K., Yun H.Y., et al. Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. J Cancer Res Clin Oncol 2000, 126(9):519-528.
39. Aceto N., Duss S., MacDonald G., Meyer D.S., Roloff T.C., Hynes N.E., et al. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res 2012, 14:R131.
40. Saunders P.T.K., Millar M.R., Williams K., Macpherson S., Bayne C., O'Sullivan C., et al. Expression of oestrogen receptor beta (ERb1) protein in human breast cancer biopsies. Br J Cancer 2002, 86:250-256.
41. Theilmeier G., Michiels C., Spaepen E., Vreys I., Collen D., Vermylen J., et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002, 99:4486-4493.
42. McIntyre T.M., Prescott S.M., Weyrich A.S., Zimmerman G.A. Cell-cell interactions: leukocyte-endothelial interactions. Curr Opin Hematol 2003, 10:150-158.
43. van Gils J.M., Zwaginga J.J., Hordijk P.L. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J. Leukoc Biol 2009, 85:195-204.
44. Bombeli T., Schwartz B.R., Harlan J.M. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), αvβ3 integrin, and GPIbα. J Exp Med 1998, 187(3):329-339.
45. Celi A., Lorenzet R., Furie B., Furie B.C. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Semin Hematol 1997, 34(4):327-335.
46. Zarbock A., Polanowska-Grabowska R.K., Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 2007, 21:99-111.
47. Totani L., Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010, 30:2357-2361.
48. Frenette P.S., Johnson R.C., Hynes R.O., Wagner D.D. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A 1995, 92:7450-7454.
49. Massberg S., Enders G., Leiderer R., Eisenmenger S., Vestweber D., Krombach F., et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998, 92:505-515.
50. Dole V.S., Bergmeier W., Mitchell H.A., Eichenberger S.C., Wagner D.D. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood 2005, 106:2334-2339.
51. Yokoyama S., Ikeda H., Haramaki N., Yasukawa H., Murohara T., Imaizumi T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol 2005, 45(8):1280-1286.
52. Blann A.D., Nadar S.K., Lip G.Y. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003, 24(24):2166-2179.
53. Jackson S.P. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med 2011, 17:1423-1436.
54. Ni H., Freedman J. Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apher Sci 2003, 28:257-264.
55. Ruggeri Z.M., Mendolicchio G.L. Adhesion mechanisms in platelet function. Circ Res 2007, 100(12):1673-1685.
56. Mosesson M.W. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992, 29(3):177-188.
57. Levy J.H., Szlam F., Tanaka K.A., Sniecienski R.M. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012, 114(2):261-274.
58. André P. P-selectin in haemostasis. Br J Haematol 2004, 126(3):298-306.
59. Cambien B., Wagner D.D. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med 2004, 10(4):179-186.
60. Modery-Pawlowski1 C.L., Kuo H.-H., Baldwin W.M., Sen Gupta A. A platelet-inspired paradigm for nanomedicine targeted to multiple diseases. Nanomedicine 2013, 8(10):1709-1727.
61. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
62. Chang H.Y., Nuyten D.S., Sneddon J.B., Hastie T., Tibshirani R., Sørlie T., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005, 102(10):3738-3743.
63. Trubetskoy V.S., Berdichevsky V.R., Efremov E.E., Torchilin V.P. On the possibility of the unification of drug targeting systems. Studies with liposome transport to the mixtures of target antigens. Biochem Pharmacol 1987, 36(6):839-842.
64. Omolola Eniola A., Willcox P.J., Hammer D.A. Interplay between rolling and firm adhesion elucidated with a cell-free system engineered with two distinct receptor-ligand pairs. Biophys J 2003, 85:2720-2731.
65. Omolola Eniola A., Hammer D.A. In vitro characterization of leukocyte mimetic for targeting therapeutics to the endothelium using two receptors. Biomaterials 2005, 26:7136-7144.
66. Ferrante E.A., Pickard J.E., Rychak J., Klibanov A., Ley K. Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. J Control Release 2009, 140(2):100-107.
67. Gunawan R.C., Auguste D.T. Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation. Mol Pharm 2010, 7(5):1569-1575.
68. Gunawan R.C., Auguste D.T. The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes. Biomaterials 2010, 31(5):900-907.
69. Gunawan R.C., Almeda D., Auguste D.T. Complementary targeting of liposomes to IL-1α and TNF-α activated endothelial cells via the transient expression of VCAM1 and E-selectin. Biomaterials 2011, 32(36):9848-9853.
70. Kibria G., Hatakeyama H., Ohga N., Hida K., Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 2011, 153(2):141-148.
71. Singh S.R., Grossniklaus H.E., Kang S.J., Edelhauser H.F., Ambati B.K., Kompella U.B. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 2009, 16(5):645-659.
72. Sapra P., Allen T.M. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004, 10(7):2530-2537.
73. Laginha K., Mumbengegwi D., Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005, 1711(1):25-32.
74. Saul J.M., Annapragada A.V., Bellamkonda R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006, 114(3):277-287.
75. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006, 20:10073-10082.
76. Xu L., Vagner J., Josan J., Lynch R.M., Morse D.L., Baggett B., et al. Enhanced targeting with heterobivalent ligands. Mol Cancer Ther 2009, 8(8):2356-2365.
77. Josan J.S., Handl H.L., Sankaranarayanan R., Xu L., Lynch R.M., Vagner J., et al. Cell-specific targeting by heterobivalent ligands. Bioconjug Chem 2011, 22(7):1270-1278.
78. Xu L., Josan J.S., Vagner J., Caplan M.R., Hruby V.J., Mash E.A., et al. Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc Natl Acad Sci U S A 2012, 109(52):21295-21300.
79. Kluza E., van der Schaft D.W., Hautvast P.A., Mulder W.J., Mayo K.H., Griffioen A.W., et al. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett 2010, 10(1):52-58.
80. Xu Q., Liu Y., Su S., Li W., Chen C., Wu Y. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 2012, 33(5):1627-1639.
81. Mack K., Rüger R., Fellermeier S., Seifert O., Kontermann R.E. Dual targeting of tumor cells with bispecific single-chain Fv-immunoliposomes. Antibodies 2012, 1:199-214.
82. Bhattacharyya S., Khan J.A., Curran G.L., Robertson J.D., Bhattacharya R., Mukherjee P. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater 2011, 23(43):5034-5038.
83. Ravikumar M., Modery C.L., Wong T.L., Sen Gupta A. Mimicking adhesive functionalities of blood platelets using ligand-decorated liposomes. Bioconjug Chem 2012, 23(6):1266-1275.
84. Ravikumar M., Modery C.L., Wong T.L., Sen Gupta A. Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro. Biomacromolecules 2012, 13(5):1495-1502.
85. Modery-Pawlowski C.L., Tian L.L., Ravikumar M., Wong T.L., Sen Gupta A. In vitro and in vivo hemostatic capabilities of a functionally integrated platelet-mimetic liposomal nanoconstruct. Biomaterials 2013, 34(12):3031-3041.
86. Modery C.L., Ravikumar M., Wong T.L., Dzuricky M.J., Durongkaveroj N., Sen Gupta A. Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery. Biomaterials 2011, 32(35):9504-9514.
87. Modery-Pawlowski C.L., Master A.M., Pan V., Howard G.P., Sen Gupta A. A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms. Biomacromolecules 2013, 14(3):910-919.
88. Nuyttens B.P., Thijs T., Deckmyn H., Broos K. Platelet adhesion to collagen. Thromb Res 2011, 127(Suppl. 2):S26-S29.
89. Pytela R., Pierschbacher M.D., Ginsberg M.H., Plow E.F., Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986, 231(4745):1559-1562.
90. D'Souza S.E., Ginsberg M.H., Matsueda G.R., Plow E.F. A discrete sequence in a platelet integrin is involved in ligand recognition. Nature 1991, 350(6313):66-68.
91. Jennings L.K. Role of platelets in atherothrombosis. Am J Cardiol 2009, 103(Suppl. 3):4A-10A.
92. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 2002, 8:1227-1234.
93. Davì G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
94. Sinha R., Kim G.J., Sie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006, 5(8):1909-1917.
95. Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010, 2(3):256-265.
96. Champion J.A., Katare Y.K., Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007, 121(1-2):3-9.
97. Shah S., Liu Y., Hu W., Gao J. Modeling particle shape-dependent dynamics in nanomedicine. J Nanosci Nanotechnol 2011, 11(2):919-928.
98. Perry J.L., Herlihy K.P., Napier M.E., Desimone J.M. PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc Chem Res 2011, 44(10):990-998.
99. Daum N., Tscheka C., Neumeyer A., Schneider M. Novel approaches for drug delivery systems in nanomedicine: effects of particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4(1):52-65.
100. Caldorera-Moore M., Guimard N., Shi L., Roy K. Designer nanoparticles: incorporating size, shape, and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010, 7(4):479-495.